Clinical Trial Search

Primary: Change From Baseline in Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12 — 8.80; 8.48; -2.48; -3.84 Episodes per 24 hours — p=<0.0001

Primary: Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint — 7.55; 7.40 percent glycosylated hemoglobin

Primary: The First Visit Onset of Efficacy as Measured by Physician Assessment — 2.2 Number of Days

Primary: Rate of Asthma Exacerbations Over the 24 Week Treatment Period — 0.205; 0.258 exacerbations per 24 patient-week period

Primary: Number or Participants With Antirecombinant Thrombin (rThrombin) Product Antibody at Baseline and Day 29 — 0; 0 Participants

Primary: Number of Participants With Death, Serious Adverse Events, Treatment-related Adverse Events (AE), AEs Leading to Discontinuation, and AEs of Hypersensitivity — 0; 1; 0…

Primary: Number of Participants With Less Than 100 Hepatitis C Virus RNA Copies/mL — 7; 7 Participants — p=<0.05

Primary: Number of Participants Having Post-operative Emesis and Nausea. — 7; 22 participants — p=<0.05

Primary: Mean Percent Change From Screening in Sperm Concentration. — 9.8; -1.3 Percent change

Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05

Primary: Change in Positive And Negative Syndrome Scale (PANSS) Total Score From Baseline to Endpoint — -38.37; -37.24 scores on a scale — p=0.784

Primary: Gene Expression Changes — 841; 1041; 1639; 628 number of regulated genes

Primary: Length of Action — 6.63; 7.02; 7.48; 7.16 minutes — p=0.359

Primary: Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) — 1.3; 2.4 Percentage of participants — p=0.0003

Primary: 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed — 90; 87; 107; 84 participants with<10 ppm exhaled CO